Pharmaceutical industry – Page 27
-
BusinessFDA warns Pfizer subsidiary over Epipen malfunctions
Manufacturer did not fully investigate reports of patients dying after auto-injector failures
-
BusinessEli Lilly to cut 3500 jobs
Company will close sites in US and China, and provide incentives for early retirement
-
ArticlePharma supply chains pick up pace
Contract suppliers are increasingly important in reducing time to market
-
BusinessAsia’s age of regulation
Safety legislation and data sharing in Asia is making progress but highlights a global challenge
-
ArticleIn-house training speeds up metabolism
Business plugs DMPK skills gap to improve drug discovery
-
-
-
BusinessMylan settles Epipen overcharging allegations
Company will pay US Department of Justice $465m for avoiding paying rebates to government healthcare systems
-
OpinionMake room for randomness in drug development
Setting free the dark horses sometimes beats the most rational planning
-
BusinessChemical and pharma bosses quit US manufacturing council
President Trump disbands the group after multiple advisers resign in protest against his stance on racism
-
WebinarCurrent topics in bioconjugation
Insights into making bioconjugates using optimal reagents and the latest techniques to create highly active and stable complexes
-
FeatureEnvironmentally benign by design
The challenge of designing drugs with biodegradability in mind
-
BusinessUS court denies Amgen appeal over Pfizer biosimilar
Amgen has lost its bid to compel Pfizer to divulge information about its version of anaemia drug Epogen
-
BusinessRoche offloads majority of rights to lebrikizumab
Deal with Dermira could be worth well over $1 billion
-
BusinessGSK stops over 30 research programmes to prioritise innovation
New boss Emma Walmsley outlines sweeping changes in order to focus on high-return drug projects
-
BusinessAstraZeneca shares tumble after antibody failure
Imfinzi and tremelimumab checkpoint inhibitor pairing fails to beat chemotherapy in lung cancer
-
BusinessNovartis coasts towards first CAR-T approval
Unanimous recommendation for CTL019 ahead of October decision builds confidence in T-cell genetic reprogramming
-
Opinion(+)-Pleuromutilin
Total synthesis is sometimes the only way to explore the chemical space around a natural product
-
BusinessBroad Institute backs central Crispr patent licensing platform
Key players submit 22 patents to pool, and urge other holders to create a one-stop shop for licensing deals
-
BusinessLilly wins chemotherapy patent appeal
Firm also settles with generic manufacturers of erectile dysfunction drug Cialis